PCI Biotech first half-year 2021 interim results
Oslo (Norway), 31 August 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first half-year 2021 results. Please find enclosed the report and presentation.
*The implementation of the amended protocol and the opening of Asian sites provided increased screening and enrolment to RELEASE in Q1, but the activity declined significantly in Q2 with only three patients included. The expected timeline for the interim analysis for potential accelerated approval is revised to 2H 2023
*Recruitment in Q3 started stronger with four patients included in July and the company continues to focus on enrolment of patients into the RELEASE study, with the emphasis on regular trial management, including overall performance evaluation and site replacement
*First US patient enrolled in the RELEASE study
*Orphan drug designation granted in South Korea
*Successful Phase I vaccination proof of concept study published in the high impact immunology journal, Frontiers in Immunology, demonstrating that fimaVacc enhances the immune response to peptide- and protein-based vaccines in healthy volunteers
*US patent granted for the use of fimaVacc in combination with immune checkpoint inhibitors
*Encouraging data on enhanced delivery of mRNA for various medical applications was presented at the UK based 12th Annual RNA Therapeutics Virtual Conference
*Established extensive research collaboration with the South Korean company OliX Pharmaceuticals, a leading developer of RNAi therapeutics
*Significantly strengthening the organisation with three highly skilled individuals; an experienced operational leader for RELEASE, and two key employees within clinical science and business development focusing on fimaVacc and fimaNAc
Per Walday, CEO of PCI Biotech, comments: “The organisation has been focused on the implementation of all the initiatives to recoup delays to the RELEASE study inflicted by the Covid-19 pandemic. On the positive side, South Korea has contributed strongly to the recruitment in 2021.Asia is a region with higher prevalence of bile duct cancer and South Korea is a key market in this region. The granting of orphan drug designation for fimaporfin in South Korea was an important step in the development of fimaChemfor bile duct cancer and a recognition of the therapeutic benefits we seek to bring to the patients.The pandemic situation is however still fluid in 2021 and we have seen fluctuating recruitment this year, which unfortunately means that we need to revise our estimated timelines. The situation is expected to improve as the vaccination rates increase going forward. We are fully focused on optimal study performance and progress, with attention to site performance and proactive management of study specific risks.The focusedefforts needed forRELEASE during the pandemic has unfortunately reduced available resources for fimaVaccand fimaNAc.We have strong confidence in the commercial potential of all our programmes and have therefore strengthened the organisation significantly, with three highly skilled employees that will play key roles indrivingthe progress of all programmes. For fimaVacc, the US patent granted for the use in combination with immune checkpoint inhibitors (ICI’s)providesimportant intellectual property for the further development of this programme. Increasing the response rates to ICI's is a main priority in the pharma industry and therapeutic cancer vaccination is a rational approachto this aim, withwell-suited characteristics of the fimaVacctechnology.For fimaNAc, we were pleased to announce a broad and exciting collaboration with OliX Pharmaceuticals in South Korea, and we continue to pursue new and value-adding collaborative opportunities.“
An online presentation in English will be held today, Tuesday 31 August 2021, at 08.30am CEST (local time). The presentation can be followed as a live webcast, access through link https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20210831_1 or the company’s website under “Investors – Reports and presentations – Webcasts”.
There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The presentation will also be presented through a teleconference, mainly facilitated for investors intending to ask questions verbally during the Q&A session.
Dial-in details for teleconference, mainly facilitated for verbal questions during Q&A session:
If you plan to use this facility, please join the event 5-10 minutes prior to the scheduled start time using the dial-in numbers below. A line mediator will provide information on how to ask questions.
Norway +47 2195 6342 / Sweden +46 4 0682 0620 / Denmark +45 7876 8490 / United Kingdom +44 20 3769 6819 / United States +1 646 787 0157. If your country is not listed, we recommend that you use the dial-in details for UK.
When prompted, provide the confirmation code or event title.
Confirmation Code: 436187
Event title: PCI Biotech Holding conference call Q2
The interim report and the presentation will also be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 31 August 2021.
For further information, please contact:
Ronny Skuggedal, CFO
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Ronny Skuggedal, CFO, PCI Biotech Holding ASA, on 31 August 2021.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Palette Life Sciences lanserar ny varumärkeswebbplats med USA:s portfölj17.9.2021 18:09:14 CEST | Pressemelding
Varumärkesuppdatering för USA och globala kommersiella produkter för behandling av ouppfyllda medicinska behov SANTA BARBARA, Kalifornien och STOCKHOLM, Sverige, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett helt integrerat globalt företag inom biovetenskap som arbetar för att förbättra patientutfall, lanserade idag sin nyligen uppdaterade webbplats Palettelifesciences.com. Webbplatsen har ett uppdaterat företagsvarumärke som stöder alla produkter i Palette Life Sciences-portföljen, och som fokuserar på minimalt invasiva behandlingar inriktade på ouppfyllda medicinska behov vid strålbehandling och interventionella onkologiska ingrepp, urologiska/urogynekologiska sjukdomar och kolorektala tillstånd. ”Vi inom Palette är stolta över vår förstklassiga produktportfölj som ger hopp åt dem med ouppfyllda medicinska behov”, säger Per G. Langö, Chief Executive Officer och Board Director för Palette Life Sciences. ”När vi bytte varumärke på vår webbplats övervägde vi hur vi bäst
Prosafe SE: bp charters Safe Zephyrus in 202217.9.2021 17:40:15 CEST | Press release
BP Exploration Operating Company Limited ('bp') has chartered the Safe Zephyrus to provide gangway connected operations to support the Seagull project at the ETAP central processing facility in the UK North Sea. The firm duration of the contract, starting Q1 2022, is 10 months with up to four months of options. The Safe Zephyrus is one of the world's most advanced and versatile accommodation vessels, complying with stringent rules in both UK and Norway and with a strong focus on reducing emissions by optimising the engine load. The value of the contract firm duration is USD 35.5 million, and the firm duration including options value is USD 49.3 million. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com 17 September 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-23BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 520, SE0014694659, 2027-09-15 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2021-09-23Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 400 mln SEK +/-200 mln SEK 1591: 1900 mln SEK +/-950 mln SEK 146: 700 mln SEK +/-350 mln SEK 581: 500 mln SEK +/-250 mln SEK 520: 600 mln SEK +/-300 mln SEK 2312: 500 mln SEK +/-250 mln SEK 5536: 400 mln SEK +/-200 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 400 mln SEK per bid 1591: 1900 mln SEK per bid 146: 700 mln SEK per bid 581: 500 mln SEK per bid 520: 600 mln SEK per bid 2312: 500 mln SEK per bid 5536: 400 mln SEK per bid Lowest permitted bid volume (co
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-24BondsSWEDISH GOVERNMENT: 1056. SE0004517290. 2032-06-01 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2021-09-24Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1056: 500 mln SEK +/-250 mln SEK 1053: 750 mln SEK +/-350 mln SEK Highest permitted bid volume (corresponding nominal amount)1056: 500 mln SEK per bid 1053: 750 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-09-28Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-09-17 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-22BillsSWEDISH T-BILL: SE0015244405. 2021-12-15 SWEDISH T-BILL: SE0016102057, 2022-06-15 SWEDISH T-BILL: SE0016787204, 2022-09-21 Bid date2021-09-22Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0015244405: 1000 mln SEK +/-500 mln SEK SE0016102057: 1000 mln SEK +/-500 mln SEK SE0016787204: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0015244405: 1000 mln SEK per bid SE0016102057: 1000 mln SEK per bid SE0016787204: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-09-24Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-09-17 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between t
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-22CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2022-03-22 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-09-10 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-09-22Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-21BondsKOMMUNINVEST I SVERIGE: 2505. SE0011414010. 2025-05-12 KOMMUNINVEST I SVERIGE: 2611, SE0012569572, 2026-11-12 KOMMUNINVEST I SVERIGE: 2805, SE0015660139, 2028-05-12 KOMMUNINVEST I SVERIGE: G23, XS1897258098, 2023-06-01 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2021-09-21Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2505: 1250 mln SEK +/-650 mln SEK 2611: 1000 mln SEK +/-500 mln SEK 2805: 500 mln SEK +/-250 mln SEK G23: 250 mln SEK +/-150 mln SEK Highest permitted bid volume (corresponding nominal amount)2505: 1250 mln SEK per bid 2611: 1000 mln SEK per bid 2805: 500 mln SEK per bid G23: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-09-23Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities